Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocriplasmin for VMT/sVMA Outcomes
NCT02322229Phase 4Completed
- Sponsor
- Alcon Inc.
- Start
- May 2015
- Primary completion
- Dec 2015
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of ocriplasmin in vitreomacular traction (VMT), vitreomacular adhesion (VMA), sponsored by Alcon Inc.. Started May 2015; status: completed.
02
Drugs
ocriplasmin
03
Conditions
vitreomacular traction (VMT)vitreomacular adhesion (VMA)
Beyond the preview
Go deeper on NCT02322229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322229.